RESTART C0168Z05 Rheumatoid Arthritis Study
A Phase 4, Multicenter, Open-Label, Assessor-Blinded Switch Study of the Efficacy and Safety of Infliximab (REMICADE) in Patients With Active Rheumatoid Arthritis Who Are Responding Inadequately to Etanercept (ENBREL) or Adalimumab (HUMIRA).
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Graz-Eggenberg, Austria
-
Wien, Austria
-
-
-
-
-
Hamilton Ontario, Canada
-
-
British Columbia
-
Vancouver, British Columbia, Canada
-
-
Manitoba
-
Winnipeg, Manitoba, Canada
-
-
Newfoundland and Labrador
-
St. John'S, Newfoundland and Labrador, Canada
-
-
Ontario
-
Toronto, Ontario, Canada
-
-
-
-
-
Helsinki, Finland
-
-
-
-
-
Bordeaux Cedex, France
-
Limoges, France
-
Montivilliers, France
-
Orleans, France
-
-
-
-
-
Frankfurt, Germany
-
Holdenfelde, Germany
-
Leipzig, Germany
-
Muenchen, Germany
-
München, Germany
-
Ratingen, Germany
-
-
-
-
-
Ashkelon, Israel
-
Beer Yaakov, Israel
-
Haifa, Israel
-
Kfar Saba, Israel
-
Ramat Gan, Israel
-
Rehovot, Israel
-
Tel-Aviv, Israel
-
-
-
-
-
Alkmaar, Netherlands
-
-
-
-
-
Madrid, Spain
-
Oviedo, Spain
-
Santiago De Compostela, Spain
-
-
-
-
-
Leeds, United Kingdom
-
London, United Kingdom
-
Wigan, United Kingdom
-
-
-
-
Alabama
-
Huntsville, Alabama, United States
-
-
Arizona
-
Paradise Valley, Arizona, United States
-
Tucson, Arizona, United States
-
-
California
-
Santa Monica, California, United States
-
-
Connecticut
-
Bridgeport, Connecticut, United States
-
-
Delaware
-
Lewes, Delaware, United States
-
-
Florida
-
Boca Raton, Florida, United States
-
Palm Harbor, Florida, United States
-
Tamarac, Florida, United States
-
Vero Beach, Florida, United States
-
-
Georgia
-
Atlanta, Georgia, United States
-
-
Illinois
-
Moline, Illinois, United States
-
Springfield, Illinois, United States
-
-
Kentucky
-
Lexington, Kentucky, United States
-
-
Maryland
-
Wheaton, Maryland, United States
-
-
Michigan
-
Saint Clair Shores, Michigan, United States
-
-
Minnesota
-
Eagan, Minnesota, United States
-
-
Missouri
-
Saint Louis, Missouri, United States
-
Springfield, Missouri, United States
-
-
New Jersey
-
Berkeley Heights, New Jersey, United States
-
Freehold, New Jersey, United States
-
-
New York
-
Albany, New York, United States
-
Syracuse, New York, United States
-
-
North Carolina
-
Chapel Hill, North Carolina, United States
-
-
Ohio
-
Columbus, Ohio, United States
-
Mayfield, Ohio, United States
-
Middleburg Heights, Ohio, United States
-
-
Oklahoma
-
Tulsa, Oklahoma, United States
-
-
Pennsylvania
-
Allentown, Pennsylvania, United States
-
Duncansville, Pennsylvania, United States
-
Wexford, Pennsylvania, United States
-
-
South Carolina
-
Charleston, South Carolina, United States
-
Greenville, South Carolina, United States
-
-
Tennessee
-
Jackson, Tennessee, United States
-
Nashville, Tennessee, United States
-
-
Texas
-
Amarillo, Texas, United States
-
Dallas, Texas, United States
-
Fort Worth, Texas, United States
-
Houston, Texas, United States
-
Mesquite, Texas, United States
-
Temple, Texas, United States
-
Tyler, Texas, United States
-
-
Virginia
-
Burke, Virginia, United States
-
Reston, Virginia, United States
-
-
Washington
-
Seattle, Washington, United States
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients must have rheumatoid arthritis
- Patients must have greater than or equal to 6 tender joints and greater than or equal to 6 swollen joints
- Patients must have inadequate disease response to etanercept or adalimumab
- Patients must have received etanercept or adalimumab in combination with methotrexate for a minimum of at least 3 months prior to the screening visit. The last dose of etanercept must have been given at least 1 week but not more than 2 weeks prior to first infliximab infusion. The last dose of adalimumab must have been administered at least 2 weeks but not more than 4 weeks prior to first infliximab infusion.
Exclusion Criteria:
- Patients who have a history of latent or active TB
- Have inflammatory disease other than rheumatoid arthritis
- Have had a chronic or recurrent infectious disease.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: 001
Infliximab3 mg/kg at week 0,2,6; Increase to 5mg/kg or 7 mg/kg based on EULAR response
|
3 mg/kg at week 0,2,6; Increase to 5mg/kg or 7 mg/kg based on EULAR response
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percent of Patients Who Achieved a EULAR (The European League Against Rheumatism) Response at Week 10
Time Frame: Week 10
|
Percent of patients who achieved EULAR response at Week 10.
EULAR response is defined based on the DAS28 score and the EULAR response criteria (Van Gestel et al, 1996 and 1999).
At a given visit, patients with a DAS28 score of ≤ 5.1 are considered EULAR responders if the improvement from baseline in their DAS28 score is greater than 0.6; Or patients with a DAS28 score > 5.1 are considered EULAR responders if the improvement from baseline in their DAS28 score is > 1.2.
|
Week 10
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percent of Patients Who Acheived EULAR Response at Week 10 and Maintained Through Week 26 Without Infliximab Dose Increase
Time Frame: Week 26
|
Percent of patients who achieved EULAR response at Week 10 and maintained through Week 26 without infliximab dose increase
|
Week 26
|
|
Percent of Patients Who Achieved EULAR Response at Week 26, Regardless of EULAR Response Status at Weeks 10, 14, and 22, With or Without Dose Increase Prior to Week 26
Time Frame: Week 26
|
Percent of patients who achieved EULAR response at Week 26, regardless of EULAR response status at Weeks 10, 14, and 22, with or without dose increase prior to Week 26
|
Week 26
|
|
Change From Baseline in Physical Function (HAQ)
Time Frame: Week 10
|
Change from baseline in physical function (HAQ) at Week 10.
HAQ assesses the degree of difficulty a person has in accomplishing tasks.
A lower HAQ score indicates less difficulty.
Change from baseline is computed as Week 10 value minus baseline value.
A negative value in change from baseline indicates an improvement.
|
Week 10
|
|
Change From Baseline in Physical Function (HAQ)
Time Frame: Week 26
|
Change from baseline in physical function (HAQ) at Week 26.
HAQ assesses the degree of difficulty a person has in accomplishing tasks.
A lower HAQ score indicates less difficulty.
Change from baseline is computed as Week 26 value minus baseline value.
A negative value in change from baseline indicates an improvement.
|
Week 26
|
|
Percent of Patients Who Achieved ACR20 at Week 10
Time Frame: Week 10
|
Percent of patients who achieved ACR20 at Week 10.
A patient is considered achieving ACR20 if the following two conditions are met: 1) An improvement of ≥ 20% from baseline in both the swollen joint count (66 joints) and tender joint count (68 joints; 2) An improvement of ≥ 20% from baseline in at least 3 of the following 5 assessments:Patient's assessment of pain visual analog scale (VAS), Patient's global assessment of disease activity (VAS), Evaluator's global assessment of disease activity (VAS), Patient's assessment of physical function as measured by the HAQ disability index, and CRP.
|
Week 10
|
|
Percent of Patients Who Achieved ACR20 at Weeks 26.
Time Frame: Week 26
|
Percent of patients who achieved ACR20 at Weeks 26.
A patient is considered achieving ACR20 if the following two conditions are met: 1) An improvement of ≥ 20% from baseline in both the swollen joint count (66 joints) and tender joint count (68 joints; 2) An improvement of ≥ 20% from baseline in at least 3 of the following 5 assessments:Patient's assessment of pain visual analog scale (VAS), Patient's global assessment of disease activity (VAS), Evaluator's global assessment of disease activity (VAS), Patient's assessment of physical function as measured by the HAQ disability index, and CRP.
|
Week 26
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CR013879
- C0168Z05 (Other Identifier: Centocor Ortho Biotech Services, L.L.C.)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.